BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32557126)

  • 1. Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
    Paciullo F; Bury L; Gresele P
    Int J Hematol; 2020 Nov; 112(5):725-727. PubMed ID: 32557126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
    Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
    Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 4. Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related Disease: A Case Report.
    Favier R; De Carne C; Elefant E; Lapusneanu R; Gkalea V; Rigouzzo A
    A A Pract; 2018 Jan; 10(1):10-12. PubMed ID: 28795988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
    Rodeghiero F; Pecci A; Balduini CL
    J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
    Zaninetti C; Barozzi S; Bozzi V; Gresele P; Balduini CL; Pecci A
    Am J Hematol; 2019 Aug; 94(8):E199-E201. PubMed ID: 31034630
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
    Pecci A; Gresele P; Klersy C; Savoia A; Noris P; Fierro T; Bozzi V; Mezzasoma AM; Melazzini F; Balduini CL
    Blood; 2010 Dec; 116(26):5832-7. PubMed ID: 20844233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 11. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
    Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 15. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
    Panzer S
    Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
    Castelli R; Gidaro A; Lambertenghi Deliliers G
    Blood Coagul Fibrinolysis; 2021 Mar; 32(2):163-166. PubMed ID: 33555693
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.